The Relationship between COVID-19 Suspected Patient’s Coagulation and Platelet Parameters and Polymerase Chain Reaction Results

Yıl 2022, Cilt: 14 Sayı: 1, 92 - 98, 14.03.2022

Mukadder Arslanbek Erdem Mahcube Cubukcu Seçil Müderrisoğlu Recai Aci Adem Keskin Eda Türe

https://doi.org/10.18521/ktd.1009234

Cited By: 3

Öz

Objective: This study aims to investigate the relationship between prothrombin time (PT), activated partial thromboplastin time (aPTT), INR (International Normalized Ratio), and D-dimer levels, platelet (PLT) levels at hospital admission, and positivity or negativity of Polymerase Chain Reaction (PCR) test results in patients with suspected coronavirus disease-19 (COVID-19) followed at COVID-19 services.
Method: This study was performed on 238 patients with the prediagnosis of COVID-19, all patients are hospitalised in Samsun city at our hospital between 11 March 2020-30 May 2020. According to COVID-19 PCR test results, PCR test negative 119 individua and PCR test positive 119 patients were included in the study. PT, aPTT, D-dimer, INR, and PLT levels were examined.
Result: While PCR test negative individuals had a mean PT value of 11.46±0.86 sec, PCR test positive patients had a mean PT value of 12.97±3.65 sec (p<0.001). There was no significant difference in mean aPTT values of PCR test positive and negative patients. Whereas INR, D-dimer increased significantly in PCR test positive patients. PLT value decreased from a mean value of 266.75±71.36*109/L in PCR test negative patients to 241.18±96.64*109/L in PCR test positive patients (p=0.002).
Conclusion: In our study, it was found that in patients who were admitted to hospital with COVID-19 suspicion and followed up in COVID-19 services, PT, D-dimer, INR, PLT values were important in detecting coagulopathy and thrombocytopenia in the group who were PCR positivity.

Anahtar Kelimeler

COVID-19, PT, aPTT, D-dimer, INR, PCR test, PLT

COVID-19 Şüphesi Taşıyan Hastaların Koagülasyon ve Trombosit Parametreleri ile Polimeraz Zincirleme Tepkimesi Sonuçları Arasındaki İlişki

Öz

Amaç: COVID-19 şüphesi ile COVID-19 servislerinde takip edilen hastaların, hastaneye başvuru sırasında yapılan Protrombin Zamanı (PT), aktive Parsiyel Tromboplastin Zamanı (aPTT), INR (International Normalized Ratio), D-Dimer düzeyleri, Trombosit (PLT) düzeyleri ile Polimeraz Zincirleme Tepkimesi (PCR) sonucunun pozitif veya negatif durumu arasındaki ilişkiyi araştırmak amaçlanmaktadır.
Gereç ve Yöntem: Bu çalışma 11 Mart 2020- 30 Mayıs 2020 tarihleri arasında, Samsun ilinde, hastanemizde COVID-19 şüphesi ile yatan 238 hasta ile yapılmıştır. COVID-19 sonuçlarına göre PCR testi negatif 119 kişi ve PCR testi pozitif 119 hasta çalışmaya dahil edilmiştir. PT, aPTT, D-dimer, INRve PLT düzeylerine bakılmıştır.
Bulgular: PT; PCR testi negatif katılımcılarda ortalama 11,46±0,86 sn değeri bulunurken, PCR testi pozitif hastalarda 12,97±3,65 sn, (p<0,01), aPTT; PCR negatif katılımcılarda ortalama 24,38±3,40 sn, PCR pozitif hastalarda ise 24,18±4,83 sn,(p>0,05) olarak bulunmuştur. D-Dimer, PCR testi negatif katılımcılarda ortalama 0,23±0,12 μg/ML, PCR testi pozitif hastalarda ise 2,10±5,60 μg/ML, (p<0,01) olarak tespit edilmiştir. INR; PCR negative katılımcılarda 0,99±0,12 değeri, PCR pozitif hastalarda ise 1,14±0,35, (p<0,01) değeri bulunmuştur. PLT; PCR testi negative katılımcılarda 266,75±71,36 (109/L), PCR testi pozitif hastalarda ise 241,18±96,64 (109/L) olarak saptanmıştır (p=0,002).
Sonuç: Çalışmamızda, hastaneye COVID-19 şüphesi ile başvuran, COVID-19 servislerinde takip edilen, PCR pozitif olan hastalarda, PT, D-Dimer, INR, PLT değerlerinin, koagülopati ve trombositopeni tespitinde önemli olduğu saptandı.

Anahtar Kelimeler

COVID-19, PT, aPTT, D-Dimer, INR, PLT, PCR Test

Kaynakça

• 1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3.
• 2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.
• 3. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. https://doi.org/10.1111/all.14238.
• 4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumoniain Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.
• 5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet.2020;395(10223):497–506.
• 6. Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, et al. Transcriptomic characteristics of broncho alveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):761–70.
• 7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novelcoronavirus-infectedpneumonia in Wuhan, China. JAMA. 2020;323(11):1061.
• 8. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poorprognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7. 9. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors formortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
• 10. Luo W, Yu H, Guo Z, Li X, Sun Y, Li J, et al. Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19). Preprints. 2020;2020020407.
• 11. Ding Y, Wang H, Shen H, Li Z, Geng J, Han H et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report fromChina. J Pathol. 2003;200(3):282–9.
• 12. Klok FA, Kruip M, Van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 2020. https://doi.10.1016/j. thromres.2020.04.013.
• 13. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J.Thromb. Haemost. 2020 http://doi.10.1111/jth.14830.
• 14. Xiong M, Liang X, Wei YD. Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. British Society for Haematology and John Wiley&Sons Ltd. 2020;(doi: 10.1111/bjh.16725).
• 15. Connors JM, Levy JH. COVID-19 and it simplications for thrombosis and anticoagulation. Blood. 2020;135(23): 2033-40. https://doi:10.1182/blood.2020006000.
• 16. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thromboticor thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;(4):0735-1097(20)35008-7.
• 17. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, Zhang Z. D-dimer levels on admission to predict in hospita lmortality in patients with Covid-19. J Thromb Haemost. 2020;18(6):1324-9.
• 18. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin. Chim. Acta. 2020;506:145-8.
• 19. Guan WJ, Ni ZY, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. https://doi.10.1056/NEJMoa2002032.